These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33345974)

  • 1. Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.
    Sunaga T; Cicali B; Schmidt S; Brown J
    Contraception; 2021 Apr; 103(4):222-224. PubMed ID: 33345974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
    Varney SJ; Guest JF
    Pharmacoeconomics; 2004; 22(17):1141-51. PubMed ID: 15612832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.
    Sivin I
    Drug Saf; 2003; 26(5):303-35. PubMed ID: 12650633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
    Prescrire Int; 2006 Apr; 15(82):50-3. PubMed ID: 16604729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
    López Del Cerro E; Serrano Diana C; Castillo Cañadas AM; González Mirasol E; García Santos F; Gómez García MT; González de Merlo G
    J Obstet Gynaecol; 2018 Oct; 38(7):979-984. PubMed ID: 29553853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
    McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
    Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of weight gain between levonorgestrel and etonogestrel implants after 12 months of insertion.
    Okunola TO; Bola-Oyebamiji SB; Sowemimo O
    Int J Gynaecol Obstet; 2019 Oct; 147(1):54-58. PubMed ID: 31265128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of 8 hormonal contraceptive options.
    Crespi S; Kerrigan M; Sood V
    Am J Manag Care; 2013 Jul; 19(7):e249-55. PubMed ID: 23919444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.
    Salem JE; Dureau P; Bachelot A; Germain M; Voiriot P; Lebourgeois B; Trégouët DA; Hulot JS; Funck-Brentano C
    JAMA Cardiol; 2018 Sep; 3(9):877-882. PubMed ID: 30073300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review.
    Callahan R; Yacobson I; Halpern V; Nanda K
    Contraception; 2015 Dec; 92(6):514-22. PubMed ID: 26363431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New forms of hormonal contraception].
    Gaspard U; Buicu C; van den Brûle F
    J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):288-91. PubMed ID: 10804374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
    Moray KV; Chaurasia H; Sachin O; Joshi B
    Reprod Health; 2021 Jan; 18(1):4. PubMed ID: 33407632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.